Dick Tracy has nothing on the wearable gadgets under development to help people better police their diabetes. Wearable technologies in its totality — which include Google Glass and the Apple Watch — are part of a booming market that’s expected to swell to $20 billion by 2015 and is further expected to grow at a compound annual growth rate of nearly 40% over the next six years.
Close to half (40%) of the U.S. adult population — roughly 126 million — is expected to develop Type 2 diabetes at some point during their lifetime, according to a study published in The Lancet Diabetes and Endocrinology in August.
Nipro Diagnostics announced that the Food and Drug Administration approved its True Metrix self-monitoring blood-glucose system, as well as the True Metrix Pro professional monitoring blood-glucose system.
The Food and Drug Administration has granted tentative approval for Basaglar (insulin glargine injection), which is used to improve glycemic control in adults with Type 2 diabetes and in combination with mealtime insulin in adults and pediatric patients with Type 1 diabetes.
Sanofi on Monday acquired the rights to Afrezza Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with Type 1 and Type 2 diabetes, from MannKind in a deal that could be worth as much as $925 million.